<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-247
Date of Submission: 2025-06-25

This report was submitted by a Patient from Phillips, Garcia and Campbell Medical Center concerning patient ANON-PX-1096. The subject is a 63-year-old female with a significant medical history including chronic kidney disease, asthma, atrial fibrillation. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Sertraline (SSRI) administered via the Topical route at a dosage of 403mg, initiated on 2025-05-25 for Major depressive disorder with the course ongoing; Levothyroxine (Thyroid hormone) administered via the Topical route at a dosage of 175mg, initiated on 2025-05-25 for Hypothyroidism with the course ongoing.

On approximately 2025-06-07, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Headache. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Fatal'. The Headache was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed significant and advised west. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 1 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Option seat college lead. Condition sit court. Help radio describe.</data>
report_id: ADR-2025-247
report_date: '2025-06-25'
patient_details:
  patient_id: ANON-PX-1096
  gender: Female
  relevant_history:
  - chronic kidney disease
  - asthma
  - atrial fibrillation
  age_at_reaction: 63
suspected_drugs:
- drug_name: Sertraline
  dosage: 403mg
  route_of_administration: Topical
  start_date: '2025-05-25'
  indication_for_use: Major depressive disorder
  drug_class: SSRI
- drug_name: Levothyroxine
  dosage: 175mg
  route_of_administration: Topical
  start_date: '2025-05-25'
  indication_for_use: Hypothyroidism
  drug_class: Thyroid hormone
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2025-06-07'
  severity: Severe
  outcome: Fatal
  intervention_required: false
- symptom_name: Headache
  onset_date: '2025-06-07'
  severity: Mild
  outcome: Not Recovered
  intervention_required: true
  intervention_details: Prescribed significant and advised west.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Not applicable
  naranjo_score: 1
reporting_facility: Phillips, Garcia and Campbell Medical Center
reporter_type: Patient
notes: Option seat college lead. Condition sit court. Help radio describe.
